Business
PRTC Leukemia Data at ASH & Begins AML Trial
PRTC Leukemia Data at ASH & Begins AML Trial.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n \n 12 December 2022\n \n \n \n \n \n \n \n PureTech Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology (ASH) Annual Meeting\n \n \n \n \n \n \n \n \n \n Data support the role of galectin-9 in multiple types of leukemia and the ability of anti-galectin-9 antibodies to provide effective anti-tumor activity in these cancers\n \n \n \n \n \n \n \n \n \n Clinical trial has initiated evaluating LYT-200 as a single agent in acute myeloid leukemia (AML) patients\n \n \n \n \n \n \n \n \n \n LYT-200 is also being evaluated in a range of metastatic solid tumors as a monotherapy and in combination with chemotherapy or an anti-PD-1 antibody; the first part of the Phase 1 trial has completed, with the combination part beginning in the first quarter of 2023\n \n \n \n \n \n \n \n \n PureTech Health plc\n \n \n (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today shared new data supporting the clinical potential of LYT-200, a fully human monoclonal antibody (mAb) designed to inhibit the activity of galectin-9, as a therapeutic agent for the treatment of leukemia. The data were shared in a scientific poster presented at the American Society of Hematology (ASH) 64th Annual Meeting. LYT-200 is a therapeutic candidate targeting galectin-9, which is expressed by tumors and immune cells and plays a key role in cancer treatment resistance. It is also in development as a treatment for a range of cancer indications with otherwise poor survival rates.\n \n \n \n \n \n \"The data we are presenting at ASH add further support to the hypothesis that galectin-9 is an important therapeutic target for not just AML but multiple blood cancers, suggesting LYT-200 may be beneficial across a range of hematologic malignancies and underscores the potential of LYT-200 in an area with significant clinical need for novel treatment regimens,\" said Aleksandra Filipovic, M.D., Ph.D., Head of Oncology at PureTech. \"The National Cancer Institute\n estimates\n that about 61,000 new cases of leukemia are diagnosed each year, including about 20,000 in AML. More than 50% of AML patients either don't respond to initial treatment or ex...